Previous preclinical work reported by Kumar et al. demonstrated in a BRAFV600E melanoma cell line that oncogenic BRAF–MAPK signaling leads to the acceleration of IFNAR1 degradation by inducing βTrcp2 expression (86). Here, BRAF is linked to melanoma.